INmune Bio Meets Milestone for CORDStrom Platform; Plans to Apply for BLA With US FDA

MT Newswires Live

Jul 20

INmune Bio (INMB) said Monday that it has successfully processed the first umbilical cord tissue under its commercial agreement with Anthony Nolan Cord Blood Bank.

The biotech company said the achievement marks a milestone under its CORDStrom platform, which is designed to improve donor variability and address manufacturing inconsistency.

INmune Bio said the commercial-ready manufacturing now supports its planned late-stage confirmation trial, as well as US, EU and UK regulatory submissions for future commercial supply.

The company expresses support for the UK Medicines and Healthcare products Regulatory Agency's draft rare therapies regulatory framework, it said.

Shares of INmune Bio were down 3.7% in recent Monday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2652357215"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2652357215\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2652357215?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-20 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652357215","market":"sh","top_or_hot":-1,"title":"INmune Bio Meets Milestone for CORDStrom Platform; Plans to Apply for BLA With US FDA","media":"MT Newswires Live","content":"<html><body><p> INmune Bio (INMB) said Monday that it has successfully processed the first umbilical cord tissue under its commercial agreement with Anthony Nolan Cord Blood Bank.</p><p>The biotech company said the achievement marks a milestone under its CORDStrom platform, which is designed to improve donor variability and address manufacturing inconsistency.</p><p>INmune Bio said the commercial-ready manufacturing now supports its planned late-stage confirmation trial, as well as US, EU and UK regulatory submissions for future commercial supply.</p><p>The company expresses support for the UK Medicines and Healthcare products Regulatory Agency's draft rare therapies regulatory framework, it said.</p><p>Shares of INmune Bio were down 3.7% in recent Monday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INmune Bio Meets Milestone for CORDStrom Platform; Plans to Apply for BLA With US FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINmune Bio Meets Milestone for CORDStrom Platform; Plans to Apply for BLA With US FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-20 20:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> INmune Bio (INMB) said Monday that it has successfully processed the first umbilical cord tissue under its commercial agreement with Anthony Nolan Cord Blood Bank.</p><p>The biotech company said the achievement marks a milestone under its CORDStrom platform, which is designed to improve donor variability and address manufacturing inconsistency.</p><p>INmune Bio said the commercial-ready manufacturing now supports its planned late-stage confirmation trial, as well as US, EU and UK regulatory submissions for future commercial supply.</p><p>The company expresses support for the UK Medicines and Healthcare products Regulatory Agency's draft rare therapies regulatory framework, it said.</p><p>Shares of INmune Bio were down 3.7% in recent Monday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INMB","symbol_name":"INmune Bio Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2652357215","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2652357215","pubTimestamp":1784551042,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"INmune Bio (INMB) said Monday that it has successfully processed the first umbilical cord tissue under its commercial agreement with Anthony Nolan Cord Blood Bank.The biotech company said the achievem","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INMB":"INmune Bio Inc","BK4588":"碎股","BK4585":"ETF&股票定投概念","LABU":"三倍做多标普生物-Direxion","BK4139":"生物科技"},"translate_title":"INmune Bio 达到 CORDStrom 平台里程碑；拟向美国FDA申请BLA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"INMB":1},"content_text":"INmune Bio (INMB) said Monday that it has successfully processed the first umbilical cord tissue under its commercial agreement with Anthony Nolan Cord Blood Bank.The biotech company said the achievement marks a milestone under its CORDStrom platform, which is designed to improve donor variability and address manufacturing inconsistency.INmune Bio said the commercial-ready manufacturing now supports its planned late-stage confirmation trial, as well as US, EU and UK regulatory submissions for future commercial supply.The company expresses support for the UK Medicines and Healthcare products Regulatory Agency's draft rare therapies regulatory framework, it said.Shares of INmune Bio were down 3.7% in recent Monday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}